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Lawson Health Research Institute, London, ON, Canada; bDepartment of Physiology and Pharmacology, Western University, London, ON,
Canada; cDepartment of Medicine, Western University, London, ON, Canada; dDepartment of Pathology, Western University, London, ON,
Canada; eInternational Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan
ABSTRACT

ARTICLE HISTORY

Both bone marrow-derived hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC)
improve glycemic control in diabetic mice, but their kinetics and associated changes in pancreatic
morphology have not been directly compared. Our goal was to examine the time course of
improvements in glucose tolerance and associated changes in β-cell mass and proliferation
following transplantation of equivalent numbers of HSC or MSC from the same bone marrow
into diabetic non-obese diabetic severe combined immune deficiency (NOD.SCID) mice. We used
transgenic mice with a targeted expression of yellow fluorescent protein (YFP) driven by the Vav1
gene promoter to genetically tag HSC and progeny. HSC were separated from bone marrow by
fluorescence-activated cell sorting and MSC following cell culture. Equivalent numbers of isolated
HSC or MSC were transplanted directly into the pancreas of NOD.SCID mice previously made
diabetic with streptozotocin. Glucose tolerance, serum insulin, β-cell mass and β-cell proliferation
were examined up to 28 days following transplant. Transplantation with MSC improved glucose
tolerance within 7 days and serum insulin levels increased, but with no increase in β-cell mass.
Mice transplanted with HSC showed improved glucose tolerance only after 3 weeks associated
with increased β-cell proliferation and mass. We conclude that single injections of either MSC or
HSC transiently improved glycemic control in diabetic NOD.SCID mice, but with different time
courses. However, only HSC infiltrated the islets and were associated with an expanded β-cell
mass. This suggests that MSC and HSC have differing mechanisms of action.
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Introduction
Bone marrow stem cell (BMSC) transplants cause
at least a temporary reversal of experimental diabetes in rodents, and possibly also in human type 1
diabetes.1-4 Trans-differentiation of BMSC directly
into pancreatic β-cells may occur for a small percentage of cells,2,4 but the reversal of hyperglycemia appear to be mainly indirect through either
increased function and/or proliferation in remaining β-cells,5-7 or suppression of immune responses
in the damaged pancreas to allow endogenous
regeneration to proceed.8 BMSC express the
CXCR4 chemokine receptor9 allowing them to
home quickly to the diabetic pancreas in response
to chemokines such as SDF-1 released from islets
during pancreatic damage.10 However, the fractions of BMSC responsible for reversing
CONTACT Dr. David J. Hill
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© 2018 Taylor & Francis
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hyperglycemia, and their respective mechanisms,
are poorly understood.
The two major BMSC lineages exist, hematopoietic stem cells (HSC) and mesenchymal stem
cells (MSC), and both may contribute to β-cell
regeneration. HSC give rise to all myeloid and
lymphoid cell lineages, including endothelial precursor cells that can contribute to microvascular
angiogenesis.11 The contribution to angiogenesis is
potentially important to β-cell regeneration since
pancreatic vascular endothelium can induce β-cell
differentiation from progenitors, while also providing key signals, such as hepatocyte growth factor (HGF), to promote β-cell proliferation and
function.12,13 When the ontogeny of HSC and
their progeny genetically tagged with yellow fluorescent protein (YFP) was tracked in the young
streptozotocin (STZ)-diabetic mouse there was an
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increased localization of HSC to the damaged
pancreas preceding a regeneration of ß-cell mass.14
HSC-derived cells expressing endothelial markers
were found within and around the islets of
Langerhans and adjacent to sites of endocrine
cell neogenesis within the pancreatic ducts.
MSC transplantation into diabetic rodents causes
a rapid reversal of hyperglycemia and may also
improve islet vascularization and β-cell mass,15-17
although the latter finding has been inconsistent.18
Human exocrine pancreas is a source of endogenous
MSC, and when isolated and expanded in vitro these
cells developed endocrine progenitor phenotypic
markers such as Pdx1 and Ngn3 expression, but
not insulin.19 As with HSC, green fluorescent protein
(GFP)-labeled MSC migrate into the pancreas following STZ-induced diabetes in mice, but their distribution differs from HSC, being mainly in the
exocrine pancreas rather than the islets.20
Thus, while endogenous HSC and MSC each
mobilize to the damaged pancreas in the presence
of hyperglycemia neither appears to be a substantial direct source of new β-cells, and they distribute
to different tissue compartments. Comparison of
the efficacy of BMSC-derived HSC or MSC in
reversing diabetes has been complicated by the
use of differing transplanted cell number, methods
of delivery, and models of rodent diabetes. In
order to directly compare their efficacy in reversing hyperglycemia, and any associated changes in
pancreatic morphology, we have utilized in this
study equivalent numbers of MSC or HSC isolated
from the same bone marrow and transplanted
directly into the pancreas of immune-deficient
diabetic mice.

Materials and methods
Animals

Mice were housed in pathogen-free surroundings with
a 12:12-h light-dark cycle in the animal facility,
Lawson Health Research Institute, London, Ontario.
Animals received food and water ad libitum. Vav1
promoter-Cre mice (B6.Cg-Tg(Vav1-cre)A2Kio/J)21
were purchased from Jackson Laboratories
(Sacramento, CA, USA) as were ROSA26-YFP mice
(B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J), and
crossed to generate double transgenic Vav-Cre/YFP

mice with YFP expression targeted to HSC and their
progeny. Double transgenic offspring (Vav-Cre;
R26R-EYFP) were identified by polymerase chain
reaction of genomic DNA using primers: iCre
sequence 5’-AGA TGC CAG GAC ATC AGG AAC
CTG; 5’-ATC AGC CAC ACC AGA CAC AGA GAT
C; and R26R-EYFP sequences oIMR0316 5’-GGA
GCG GGA GAA ATG GAT ATG; oIMR0883 5’AAA GTC GCT CTG AGT TGT TAT; oIMR4982
5’-AAG ACC GCG AAG AGT TTG TC, as described
by us previously.14 NOD.SCID mice (NOD.CB17PrkdcSCID/NcrCrl) were obtained from Charles River
Laboratories (Sherbrooke, ON, Canada) and served as
recipients of HSC or MSC transplantation.
Fluorescent activated cell sorting

Three month-old Vav1-Cre/YFP male mice were
euthanized, the femur and tibia dissected, and
bone marrow flushed into a sterile Petri dish containing Dulbecco’s modified Eagle's medium
(DMEM) supplemented with 100 units/ml penicillin, fetal bovine serum (10 % v/v), streptomycin
(100 µg/ml), L-glutamine (4 mM) and sodium
pyruvate (1 mM). Dispersed marrow cells were
centrifuged at 1200 rpm for 4 min at 4°C. The
supernatant was aspirated and the pellet re-suspended in 1 ml red blood cell lysis buffer
(Sigma-Aldrich, Oakville, ON, Canada) and incubated at 4°C for 5 min. Dulbecco’s modified
Eagle’s (DME)/F12 medium (5 ml) and 10% v/v
heat-inactivated FBS were added to each tube and
the cells dispersed and filtered through a sterile 40
µm filter. Cell suspensions from YFP-expressing
mice animals were pooled, as were those from
controls. YFP–expressing or non-expressing cells
(300 µl) + 40 µl 7-aminoactinomycin D (7-AAD)
as a cell viability indicator were subjected to FACS,
as described previously.22
Isolation and propagation of bone marrow MSC

Bone marrow fractions were prepared from the
same male Vav1-Cre/YFP transgenic mice as
described above to isolate MSC using a previously
published protocol.23 Bone marrow was transferred into ventilated cap T-75 tissue culture flasks
containing 10 mL DMEM and incubated in a
humidified incubator at 37°C with 5 % CO2.

ISLETS

Second passage MSC were used for transplant.
Phenotypic identity of MSC was confirmed using
flow cytometry for the presence of CD44, CD90
and CD117, as described by us previously.24
Experimental diabetes

Female NOD.SCID mice from each litter received
either a subcutaneous injection of 35mg/kg STZ
(Sigma-Aldrich) freshly prepared in citrate buffer
(pH 4.5), or a sham injection consisting of citrate
buffer alone, at 2 and 5 days of age. The latter
animals served as controls. Some animals were
sacrificed 72h following the last treatment with
STZ to confirm destruction of the β-cells by
immunohistochemistry of the pancreas. A nonfasted random blood glucose was measured using
a glucometer (Accu-Check, Roche) 14 days after
the last STZ injection to confirm the presence of
diabetes (glucose >11 mM).
Intra-pancreatic cell transplant

As BMSC administered intravenously become
lodged in the lungs and spleen with only a small
proportion reaching the target organ,25 we performed direct intra-pancreatic grafting as
described previously by Bell et al.26 MSC or HSC
derived from Vav1-Cre/YFP male mice were
transplanted into the pancreata of 20 days old,
STZ-treated or control NOD.SCID female mice.
Recipient mice were anaesthetized with isofluorane and a laparotomy was performed under sterile
conditions to expose the spleen and the pancreas.
HSC or MSC were microinjected (1 × 106 cells
suspended in 150µl PBS) into the splenic portion
of pancreas with a 25 G needle. Control animals
received identical surgical intervention but were
given a sham intra-pancreatic injection of PBS
only.
Glucose tolerance test and insulin measurement

An intraperitoneal glucose tolerance test (IPGTT)
was performed at days 7, 21 and 28 after HSC or
MSC transplant into NOD.SCID mice, immediately before sacrifice. A bolus of 2g/kg glucose
was injected in the peritoneal space (i.p.) and
blood glucose monitored at 5, 15, 30, 60, 90 and
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120 min. Glucose was measured by glucometer
after lancing the tail vein. Blood was collected at
sacrifice immediately after the glucose measurement at 120 min and serum insulin measured
using an Ultrasensitive Insulin ELISA (range
0.02-1 ng/ml) (Crystal Chem., IL, USA).
Immunohistochemistry

NOD.SCID mice transplanted with HSC or MSC were
sacrificed at 7, 21 or 28 days following transplant. The
pancreas was removed and weighed, fixed in 4% paraformaldehyde, and embedding in OCT (Tissue-Tek,
VWR International, Mississauga, ON, Canada).
Cryosections (7 μm thickness) were placed on
SuperFrost Plus glass slides (Fisher Scientific,
Toronto, ON, Canada) and stored at −80°C with
desiccant in an airtight box. Transplanted HSC and
their progeny were identified by fluorescence microscopy for YFP. To determine the presence of the male
transplanted MSC within the pancreas of female recipient mice, detection of the Y-chromosome was performed using the Mouse IDetect Y chromosome
fluorescence in situ hybridization (FISH) kit (Empire
Genomics, Buffalo, NY, USA).
Fluorescence immunohistochemistry co-staining
was performed for insulin and Ki67 to detect colocalization of DNA synthesis in β-cells, and for
CD31 and insulin to calculate the density of endothelial cells per islet. Non-specific binding was prevented
with blocking solution (Sniper Universal block;
Biocare Medical, Concord, CA, USA) before incubation with rabbit anti-GFP (1:200; Abcam, Toronto,
ON, Canada) for YFP detection, mouse or rabbit
anti-insulin (1:2000, Sigma Chemical Co., St Louis,
MO; and 1:300, Santa Cruz respectively), mouse
anti-Ki67 (1:50 BD Biosciences, Mississauga, ON,
Canada), or a monoclonal antibody against CD31
(1:50, Hycult Biotech, Plymouth Meeting, PA, USA)
overnight in a humidified chamber at 4°C. After washing with PBS, secondary antibodies were applied
(1:400 donkey anti-goat or anti-rabbit, AlexaFluor
488 and 555; or 1:400 goat anti-mouse, Alexafluor
555 (Invitrogen Canada Inc., Burlington, ON,
Canada) for 1h at room temperature. Nuclei were
counterstained using 4, diamidino-2-phenylindole
(1:1000; DAPI; 5 µg/ml) before mounting with coverslips using Dako fluorescent mounting medium
(Dako, Mississauga, ON, Canada). To establish
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specificity of the antibodies controls included substitution of the primary antibody with non-immune
serum, or omission of the secondary antibody.
To detect β-cell mass, immunohistochemistry for
insulin was performed using a modified avidin-biotin peroxidase method as described previously.27
Following incubation with rabbit anti-insulin sections were incubated with biotinylated horse antimouse secondary antibody (Vector Laboratories,
Burlington, Canada), and diaminobenzoate (DAB)
(Biogenex Inc, Fremont, CA) was used as the chromogen. Sections were counter-stained with Carazzi’s
haematoxylin and morphometric analysis performed
by light microscopy.

Morphometric analysis

Histomorphometry was performed using a Carl
Zeiss Axioskop fluorescent microscope (Carl
Zeiss, Inc., New York, NY, USA) with QImaging
MicroPublisher 3.3 Real Time Viewing camera
(QImaging, Burnaby, BC, Canada). Image analysis
was performed using Northern Eclipse Version 7.0
morphometric analysis software (Empix Imaging,
Inc., Mississauga, ON, Canada). For each section
the following were determined: the total area of
pancreatic tissue, the area of the pancreatic tissue
represented by endocrine cells, the percentage of
area occupied by β-cells (insulin-positive) within
each islet, the percentage of insulin-positive cells
that co-stained for Ki67, and the number of CD31positive cells per mm2 of islet.

Statistical analysis

Data is presented as mean ± SEM from between 4
and 12 animals per experimental group. Statistical
analysis was performed using two-way ANOVA
and Bonferroni’s post hoc test for multiple comparisons, or by t-test. A value of p<0.05 was considered statistically signiﬁcant. For morphometric
analysis, three random sections (separated at least
for 150μm) from each pancreas were analyzed. The
β-cell mass per pancreas was calculated by multiplying the area of pancreas occupied by β-cells by
the pancreatic weight. For statistical analyses the
Prism software package (Graphpad Software Inc,
La Jolla, CA) was utilized.

Results
Effects of STZ with or without cell transplants on
body weight and fasting glucose

The mean values for body weight and fasting
blood glucose 7, 21 and 28 days following sham
or pancreatic transplants of HSC or MSC in NOD.
SCID STZ-treated mice compared to control animals are shown in Table 1. Body weight did not
significantly differ with time after treatment, or
between treatments groups. Mice receiving STZ
alone became significantly hyperglycemic compared to controls at days 21 and 28. Fasting
blood glucose remained elevated in STZ-treated
mice transplanted with MSC but was significantly
reduced compared with STZ treatment alone in
HSC-transplanted animals at day 21. However,
neither MSC or HSC transplant were able to prevent hyperglycemia 28 days after transplant

Changes in glucose tolerance and circulating
insulin

We examined if intra-pancreatic transplant of
either HSC or MSC from Vav1-Cre/YFP mice
could improve either glycemic control following
an IPGTT or circulating insulin in STZ-treated
NOD.SCID animals. IPGTTs were performed at
7, 21 and 28 days following cell transplantation
compared with STZ-treated NOD.SCID shaminjected control animals, and the area under the
curve (AUC) calculated. Mice given STZ but no
Table 1. Changes in fasted blood glucose and body weight at
7, 21 and 28 days following transplant of HSC or MSC into STZdiabetic NOD.SCID mice compared to non-diabetic control
animals.
Time post-transplant
(days)
7

21

28

Treatment
Control
STZ
HSC
MSC
Control
STZ
HSC
MSC
Control
STZ
HSC
MSC

Glucose
(mmol/l)
6.3 ± 0.8
9.9 ± 1.9
13.5 ± 1.9
9.2 ± 1.8
5.4 ± 0.5
22.1 ± 2.8
7.2 ± 0.7*
16.5 ± 3.5
5.9 ± 0.2
24.7 ± 3.3
28.2 ± 5.2
24.8 ± 6.3

Body weight
(g)
14.8 ± 1.1
11.6 ± 0.9
13.5 ± 1.6
14.7 ± 2.4
20.2 ± 0.8
15.7 ± 0.6
19.4 ± 0.9
19.2 ± 0.8
21.5 ± 1.2
17.5 ± 1.0
17.3 ± 1.2
14.4 ± 1.2

Values show ± SEM, * p<0.05 vs STZ at day 21 (One way ANOVA,
Bonferroni post-hoc test). n = 4–10 animals.

ISLETS

cell transplant experienced severe glucose intolerance following an IPGTT at all time points
(Fig. 1). Mice treated with STZ which received
MSC, but not those transplanted with HSC,
showed significantly better glucose control with a
lower AUC compared to non-transplanted, STZtreated NOD.SCID controls. At 21 days, both MSC
and HSC transplants resulted in a significantly
lower AUC compared to STZ-treated animals
However, 28 days after pancreatic transplant all
beneficial effects of HSC or MSC on glycemic
control were lost. Serum insulin values were significantly reduced following STZ treatment at days
7 and 21 but returned to control values in mice
transplanted with MSC, but not HSC at day 21
(Fig. 2). However, the increased insulin levels seen
with MSC were not maintained at 28 days at which
time they were similar to STZ-treated, sham-operated mice. Thus, MSC had a rapid beneficial effect
on glucose tolerance at day 7 and 21 in STZtreated mice, with a significant increase in circulating insulin at day 21. Conversely, HSC only
improved glucose tolerance after three weeks
although circulating insulin was still reduced compared to sham-operated controls. The positive
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effects of either MSC or HSC on glucose control
were not sustained at 28 days.
Changes in pancreatic morphology

Despite the beneficial effects of MSC transplant on
glycemic control, when the presence of transplanted MSC from male donors within the female
pancreas was examined by FISH at day 7–28 they
were not detectable. In contrast, transplanted YFPexpressing HSC were still detectable within the
pancreas, and particularly associated with islets,
at 21 days but much less so at 28 days (Fig. 3).
No histological evidence of pancreatitis was
observed as a result of the direct pancreas
injection.
Beta-cell mass was calculated following immunostaining for insulin, as shown in representative images
for control, STZ-treated, and stem cell transplanted
animals in Fig. 4. No significant differences in β-cell
mass were observed 7 days after transplant of MSC
or HSC compared to sham-operated STZ-treated
NOD.SCID controls. At day 21 STZ-treated NOD.
SCID mice transplanted with HSC had a significant
increase in β-cell mass compared to STZ-treated,

Figure 1. Glucose tolerance tests were performed on control, citrate buffer-treated mice (sham transplant, ●, open bar), mice treated
with STZ (sham transplant, ■, hatched bar), and those who received STZ followed by intra-pancreatic transplant of HSC (▼, stipple
bar) or MSC (◆, closed bar) at 7 (A), 21 (B) or 28 (C) days post-grafting. The areas under the curve are shown in D. Values show mean
± SEM; # p < 0.05, ## p < 0.01 vs. STZ alone; n = 4–12 animals per time point.
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Figure 2. Serum insulin levels in control (citrate buffer-treated, sham transplant, open bar), mice treated with STZ (sham transplant,
hatched bar), and those who received STZ followed by intra-pancreatic transplant of MSC (stippled bar) or HSC (solid bar) at 7, 21, or
28 days post-transplant. Values show mean ± SEM; # p<0.01 vs. control, * p < 0.05 vs. STZ alone for same time point; n = 4–8
animals per time point.

Figure 3. A) Presence of transplanted HSC from Vav1-Cre transgenic mice expressing YFP within the spleen of donor animals as a
positive control. The arrows indicate YFP-expressing splenocytes. HSC were also located within the pancreatic islets (I) of recipient
NOD.SCID mice 21 days (B) or 28 days (C) after transplantation. In each case the arrows indicate YFP-expressing HSC-derived cells.
Cell nuclei are visualized using DAPI stain (blue). The magnification bar indicates 100 µm.

Figure 4. Immunohistochemical localization of insulin (brown) in β-cells within representative islets of Langerhans (arrows) within
pancreata of control mice (A), mice treated with STZ (B), STZ with subsequent transplant of HSC (C) or STZ with subsequent transfer
of MSC (D). The magnification bar indicates 100 µm.

sham-operated controls, such that the β-cell mass
was equal to that of non-STZ-treated animals
(Fig. 5). However, this relative gain in β-cell mass
was not maintained at 28 days. To determine if this
represented a subsequent loss of β-cells we measured

the mean islet area occupied by insulin immunoreactive cells. For mice transplanted with HSC the
mean ± SEM area of an islet at day 21 was 1590
±292 μm2 of which 88% was occupied by insulinpositive cells, whilst at day 28 the mean area of an
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Figure 5. Pancreatic β-cell mass in control (citrate-buffer injected, sham transplant, open bar), mice treated with STZ (sham
transplant, hatched bar), and those who received STZ followed by intra-pancreatic transplant of HSC (stippled bar) or MSC (closed
bar) at 7, 21 or 28 days post-transplant. Values show mean ± SEM; # p < 0.05 vs. control, * p < 0.05 vs. STZ alone, n = 4–11 animals
per time point.

islet was 1631±92 μm2 but with only 62% being
occupied by insulin-positive cells. The maintenance
of mean islet size suggests that at 28 days many βcells may have become exhausted of insulin and no
longer demonstrated insulin immunoreactivity. No
significant changes were seen in β-cell mass in mice
transplanted with MSC cells at any time point.
We next examined the relationship across all
experimental groups between β-cell mass at time
of sacrifice and the AUC during an IPGTT
(Fig. 6). No significant relationship (R2 = 0.11)
existed at 7 days post-HSC or MSC transplant,
despite the beneficial effects of MSC on glycemic
control. However, at day 21 an inverse relationship
existed between AUC and log β-cell mass with a
slope significantly different from zero (R2 = 0.65,
p<0.001). This was also seen at day 28 (R2 = 0.52,
p<0.05). This analysis indicated that glycemic control was strongly dependent on the ß-cell mass of
the animal, but that the ability of MSC to improve
glycemic control at day 7 was not related to β-cell
mass.
To determine the cellular compartments within
the pancreas that contributed to an increased βcell mass at day 21 after HSC transplant we examined the number of islets per area of pancreas, and
the number of small, extra-islet endocrine cell
clusters. The number of islets was increased compared to the NOD.SCID STZ-treated control mice
on day 21, but not so the number of smaller
endocrine clusters (Fig. 7A and B). No changes

in islet or cluster number were seen in NOD.
SCID STZ-treated mice after transplant of MSC.
To determine if the increase in ß-cell mass at day
21 after HSC transplant was due to an increased
cell proliferation, Ki67 was co-localized within βcells and the abundance of Ki67-positive cells was
found to be significantly increased compared to
STZ-treatment alone at 21 days post-transplant,
but not at 28 days (Fig. 7C). Beta-cell proliferation
in both islets and clusters contributed to the
increase on day 21.
Since the ability of transplanted HSC to increase
β-cell mass following STZ treatment has been
shown previously to be associated with their transdifferentiation into cells expressing endothelial progenitor cell markers,2 we examined the density of
vascular endothelial cells within islets from control
and STZ treated mice, with and without transplant
of MSC or HSC, 21 days following transplantation.
CD31-immunoreactive cells were identified within
control islets (Fig. 8). Following STZ the β-cell mass
was substantially reduced, as were the number of
CD31-positive cells per islet area. However, when
quantified, the number of endothelial cells per mm2
of islet was not significantly different from nontransplanted animals (Table 2).
The results show that HSC transplant was associated with an increase in β-cell mass, proliferation, and number of islets, and improved glucose
tolerance after three weeks. In contrast MSC transplant resulted in an early improvement in glycemic
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Figure 6. Correlation between the AUC following an IPGTT and
β-cell mass at 7, 21 and 28 days following transplant of MSC or
HSC. Control mice are represented by circles, STZ-treated mice
by squares, STZ+MSC by diamonds, and STZ+HSC by triangles.
The line of best fit is shown (day 7 R2 = 0.11, day 21 R2 = 0.65,
day 28 R2 = 0.52).

control, but no change in β-cell mass or islet
morphology.
Discussion
This study provided a direct comparison of HSC
and MSC derived from the same bone marrow for

their ability to reverse diabetic hyperglycemia and
the association with β-cell mass. Whilst both were
effective at improving glucose tolerance, there
were substantial differences in both time course
and resulting changes in β-cell recovery.
Although transplanted YFP-expressing HSC or
progeny could be detected in the pancreas up to 21
days post-transplant, no MSC remained detectable
by FISH after 7 days. This agrees with previous
reports that MSC transplanted into diabetic rats
were detectable in pancreas for 7–8 days, but not
thereafter.28,29 This may be explained by the peak
release of SDF-1 from injured pancreas 5–7 days
after the insult, responsible for activating the
CXCR4 receptor on MSC to promote migration.29
Despite a rapid clearance from the pancreas, transplanted MSC were able to reverse diabetic hyperglycemia after 7 days and the effect persisted until 21 days
post-transplant, accompanied by a significant increase
in serum insulin levels. However, no significant regeneration of β-cell mass or change in the number of islets
or small pancreatic endocrine clusters occurred compared to non-transplanted mice. This implies a rapid
impact of MSC on the functionality of remaining βcells in the diabetic animals, most likely through the
release of trophic factors since the effects persisted
after MSC were no longer detectable. Rackham et al.30
identified annexin A1 (ANXA1) in MSC as an important modulator of glucose-stimulated insulin release
from islets in vitro and in vivo. A recent study from the
same group analyzed the expression of mRNA for
ligands expressed by adipose-derived human MSC
that could interact with G-protein coupled receptors
highly expressed by human β-cells.31 Thirty-six such
genes were identified, including ANXA1. In addition
to release in soluble form such ligands were also localized within MSC-derived extracellular matrix, and
co-culture of MSC matrix with mouse or human islets
improved glucose-stimulated insulin secretion.
However, the rapid ability of MSC to enhance insulin
release is likely to be multifactorial, since MSC-conditioned culture medium has also been shown to contain
trophic molecules such as interleukin (IL)-6, IL-8,
vascular endothelial growth factor (VEGF)-A, and
HGF.32 Co-culture with islets demonstrated an
increased expression of anti-apoptotic genes such as
Bcl2 and Bcl-xl, and the VEGFR2 and Tie2 receptors
within β-cells.33 When islets isolated from STZ-diabetic mice were incubated with MSC there was also an
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Figure 7. Number of islets (A) or extra-islet endocrine clusters (B) per mm2 present in pancreata from control mice (citrate buffer
injected, sham transplant, open bar), mice treated with STZ (sham transplant, hatched bar), and those who received STZ followed by
intra-pancreatic transplant of HSC (stippled bar) or MSC (closed bar) at 7, 21 or 28 days post-grafting. The percent labelling of insulin
immunoreactive cells with Ki67 is shown for all ß-cells (C). Values show mean ± SEM; # p < 0.05 vs. control, * p < 0.05 vs. STZ alone;
n = 4–10 animals per time point.

increased expression of Pdx1, which is necessary for
insulin synthesis.28 The consensus of these and other
findings supports the ability of secreted factors from
MSC to mobilize increased insulin secretion in vivo,
but it is unclear if MSC also release proteins that can
induce β-cell regeneration. Analysis of human BMSC
for their ability to promote β-cell regeneration when
transplanted into STZ-diabetic NOD.SCID mice identified a regenerative sub-fraction of cells that selectively activated Wnt signaling pathways within the βcells, and contributed to their proliferation.34
Similarly, Park et al.35 demonstrated that co-transplantation of human MSC with isolated islets
enhanced islet angiogenesis, which could support
their survival and proliferation, and this has been
linked by others to signaling via the Akt and ERK1/2
pathways in β-cells.36 It is also possible that MSC
induce β-cell neogenesis from the pancreatic ducts
following pancreas injury,37 although this process
would be expected to take several weeks before a

substantial change in β-cell mass was detected.
Additionally, human pancreatic exocrine tissue contains resident MSC that are able to generate endocrine
progenitor cell markers following repeated cell passaging in vitro.38 In contrast to our findings a single
injection of human MSC caused an increase in β-cell
mass in STZ-diabetic mice, due to a suppression of
apoptosis.33 In our experimental design transplantation of MSC occurred 15 days after the final STZ
injection, by which time all damaged β-cells would
have largely been lost through apoptosis. These experiments would not, therefore, reveal beneficial effects of
MSC on β-cell survival. It is possible that MSC derived
from different tissue sources might have varying
effects or potency on enhancing β-cell mass. Our
results show that this did not occur with allografts of
bone-marrow-derived MSC in immune-deficient
mice over a four week period.
In the present study the improvement of glycemic control was not sustained beyond 21 days
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Table 2. Changes in the number of CD31-immunopositive
endothelial cells per mm2 of islet following 21 days following
transplant of HSC or MSC into STZ-diabetic NOD.SCID mice
compared to non-diabetic control animals.
Treatment
Control
STZ
MSC
HSC

CD31-positive cells
1.11 ± 0.02
0.07 ± 0.01
0.06 ± 0.01
0.06 ± 0.01

Values show ± SEM, n = 4–9 animals

Figure 8. Immunohistochemical localization of CD31 (red,
arrows) and insulin (green) within representative islets of
Langerhans within the pancreas of control mice (A), mice
treated with STZ alone (B), or those given STZ with a subsequent transplant of MSC (C), 21 days after cell transplant. Cell
nuclei are visualized using DAPI stain (blue). The magnification
bar indicates 100 µm.

following a single treatment with MSC. However,
repeated administration of MSC to diabetic
immune-competent rats did cause a sustained
improvement in both insulin secretion and glucose
tolerance.39 Similarly, in immune-competent diabetic mice administration of MSC resulted in a
long-term reversal of hyperglycemia associated

with a reduction in the abundance of autoreactive
T cells and a change in the Th1/Th2 ratio towards
an anti-inflammatory cytokine profile.40 The
absence of a cytoprotective immunological
response in the NOD.SCID may have limited any
possible indirect immune effects on β-cell
regeneration.
Transplant of HSC into diabetic NOD.SCID
mice also improved glycemic control but this was
not seen until 21 days post-transplant and was not
accompanied by a significant increase in circulating insulin. However, since insulin was measured
at the endpoint of a IPGTT the insulin excursion
may have already subsided. Unlike MSC, HSC
treatment significantly increased β-cell mass to
that of control animals, although this was not
sustained following a single transplant. The
increased β-cell mass was associated with an
increase in β-cell proliferation and the number of
islets, suggesting that HSC may have enhanced
both β-cell neogenesis from progenitors and an
increased proliferation in remaining β-cells within
islets. This was not associated with an angiogenic
effect of HSC since the density of islet endothelial
cells was not significantly changed 21 days after
transplantation.
Others have also attempted to analyze HSC fractions that promote β-cell regeneration. Bell et al.26
separated human umbilical cord blood stem cells
into aldehyde dehydrogenase (ALDH) high or low
expressing fractions and tested each for their ability
to reverse diabetes in NOD.SCID mice. The ALDH
high, but not low cells, demonstrated increased β-cell
proliferation and islet vascularization but did not
transdifferentiate into insulin-expressing cells.
Further characterization showed that the ALDH
high cells were enriched for endothelial precursor
cells. A subsequent study further identified the active
cell fraction as bearing hematopoietic lineage markers
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such as CD34 and CD133 but not CD38.41 A different
approach was adopted by Luo et al.42 who separated
mouse BMSC using a variety of HSC cell surface
markers. A Sca+/Mac-1− cell fraction was shown to
be most effective in infiltrating islets in vivo. Finally,
small embryonic-like bone marrow-derived HSC with
a Fr25 lin– phenotype were shown to be most effective
in infiltrating islets and aligning beside potential sites
of β-cell neogenesis on pancreatic ducts in the diabetic
mouse.43 The precise signaling mechanisms responsible for initiation of β-cell proliferation by HSC are
unknown, but there are a variety of potential target
cells. In addition to a direct action on remaining but
proliferatively quiescent β-cells, highly proliferative βcell progenitors have been identified in both the
rodent and human pancreas. We identified multi-lineage potential progenitors within islets and in the small,
extra-islet endocrine clusters44 that contain some
insulin but poorly express the glucose transporter 2
(Ins+Glut2LO cells), rendering them glucose
unresponsive.45 Under metabolic stress Ins+Glut2LO
cells differentiated into mature, functional β-cells.
Ins+Glut2LO cells were present in human and mouse
pancreas throughout life but decreased in abundance
with age.46 Whilst Ins+Glut2LO cells may represent a
resident population of β-cell progenitors there is evidence that at least some may represent a transient
phenotype between α-and β-cells. By lineage tagging
α-cells in mice a transdifferentiation of α-cells to
Ins+Glut2LO cells was demonstrated with the latter
being located in clusters and the islet periphery.47
The α-cell population was subsequently repleted by
neogenesis. A similar transdifferentiation was identified in human islets following transplant into
immune-deficient animals. Recently, highly proliferative α-cell-like progenitors have also been described in
the human pancreas throughout life,48 as well as
newly-committed endocrine progenitors in the
mouse pancreas that selectively express high ALDH
activity.49 Either of these populations could be progenitors to Ins+Glut2LO cells, or distinct progenitor
pools that are amenable to HSC-induced expansion
and differentiation to become functional β-cells.
In summary, we showed that a single intrapancreatic injection of either MSC or HSC from
mouse bone marrow can transiently improve glycemic control in diabetic mouse recipients, but
with different time courses and likely different
mechanisms of action. We speculate that any
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contribution of endogenous bone marrow stem
cells to the ability of pancreatic β-cells to regenerate, perhaps in early life, will involve the additive
action of MSC and HSC.
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